Authors focused on ibrutinib (Selleck Chemicals, Houston, TX, USA) and ibrutinib combined with dactolisib (Selleck Chemicals, Houston, TX, USA), a phosphoinositide 3-kinase/mammalian target of rapamycin kinase (PI3K/mTOR) inhibitor, on ten different breast cancer cell lines in vitro. The gene discussed is MTOR; the disease is breast cancer.